• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PLx Pharma Inc.

    3/16/21 4:15:20 PM ET
    $PLXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLXP alert in real time by email
    SC 13G 1 levelone13g.htm SCHEDULE 13G Schedule 13G
    
    
    
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    
    SCHEDULE 13G
    
    Under the Securities Exchange Act of 1934
    
    (Amendment No. ___)*
    
    PLx Pharma Inc.
    --------------------------------------------------------------------------------
    (Name of Issuer)
    
     Common Stock, $0.001 par value
    --------------------------------------------------------------------------------
    (Title of Class of Securities)
    
     72942A107
    --------------------------------------------------------------------------------
    (CUSIP Number)
    
     November 18, 2020
    --------------------------------------------------------------------------------
    (Date of Event Which Requires Filing of this Statement)
    
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    
    	[_]  Rule 13d-1(b)
    
    	[x]  Rule 13d-1(c)
    
    	[_]  Rule 13d-1(d)
    
    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    
    
    ________________________________________
    
    CUSIP No.	72942A107
    --------------------------------------------------------------------------------
    (1)	Name of Reporting Person:  Level One Partners, LLC
    --------------------------------------------------------------------------------
    (2)	Check the appropriate box if a member of a Group (see instructions)
    (a)  [X]
    (b)  [  ]
    --------------------------------------------------------------------------------
    (3)	Sec Use Only
    --------------------------------------------------------------------------------
    (4)	Citizenship or Place of Organization:  Commonwealth of Virginia
    --------------------------------------------------------------------------------
    Number of Shares Beneficially Owned by Each Reporting Person With:
    
    (5)	Sole Voting Power:  0
    --------------------------------------------------------------------------------
    (6)	Shared Voting Power:  2,772,643
    --------------------------------------------------------------------------------
    (7)	Sole Dispositive Power:  0
    --------------------------------------------------------------------------------
    (8)	Shared Dispositive Power:  2,772,643
    --------------------------------------------------------------------------------
    (9)	Aggregate Amount Beneficially Owned by Reporting Person: 2,772,643
    --------------------------------------------------------------------------------
    (10)	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions):
    [  ]
    --------------------------------------------------------------------------------
    (11)	Percent of class represented by amount in row (9):	12.7%
    --------------------------------------------------------------------------------
    (12)	Type of Reporting Person (See Instructions):  HC
    --------------------------------------------------------------------------------
    
    
    CUSIP No. 72942A107
    --------------------------------------------------------------------------------
    (1)	Name of Reporting Person: 	Robert D. Hardie
    --------------------------------------------------------------------------------
    (2)	Check the appropriate box if a member of a Group (see instructions)
    (a)  [X]
    (b)  [  ]
    --------------------------------------------------------------------------------
    (3)	SEC Use Only
    --------------------------------------------------------------------------------
    (4)	Citizenship or Place of Organization:  United States of America
    --------------------------------------------------------------------------------
    Number of Shares Beneficially Owned by Each Reporting Person With:
    
    (5)	Sole Voting Power:  875,000
    --------------------------------------------------------------------------------
    (6)	Shared Voting Power:  2,772,643
    --------------------------------------------------------------------------------
    (7)	Sole Dispositive Power:  875,000
    --------------------------------------------------------------------------------
    (8)	Shared Dispositive Power:  2,772,643
    --------------------------------------------------------------------------------
    (9)	Aggregate Amount Beneficially Owned by Reporting Person:  3,647,643
    --------------------------------------------------------------------------------
    (10)	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions):
    [  ]
    --------------------------------------------------------------------------------
    (11)	Percent of class represented by amount in row (9):	16.7%
    --------------------------------------------------------------------------------
    (12)	Type of Reporting Person (See Instructions):  IN, HC
    --------------------------------------------------------------------------------
    
    
    
    CUSIP No. 72942A107
    --------------------------------------------------------------------------------
    (1)	Name of Reporting Person: 	Molly G. Hardie
    --------------------------------------------------------------------------------
    (2)	Check the appropriate box if a member of a Group (see instructions)
    (a)  [X]
    (b)  [  ]
    --------------------------------------------------------------------------------
    (3)	SEC Use Only
    --------------------------------------------------------------------------------
    (4)	Citizenship or Place of Organization:  United States of America
    --------------------------------------------------------------------------------
    Number of Shares Beneficially Owned by Each Reporting Person With:
    
    (5)	Sole Voting Power:  0
    --------------------------------------------------------------------------------
    (6)	Shared Voting Power:  2,772,643
    --------------------------------------------------------------------------------
    (7)	Sole Dispositive Power:  0
    --------------------------------------------------------------------------------
    (8)	Shared Dispositive Power:  2,772,643
    --------------------------------------------------------------------------------
    (9)	Aggregate Amount Beneficially Owned by Reporting Person:  2,772,643
    --------------------------------------------------------------------------------
    (10)	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions):
    [  ]
    --------------------------------------------------------------------------------
    (11)	Percent of class represented by amount in row (9): 12.7%
    --------------------------------------------------------------------------------
    (12)	Type of Reporting Person (See Instructions):  IN, HC
    --------------------------------------------------------------------------------
    
    
    
    SCHEDULE 13G
    
    Item 1(a)	Name of Issuer:  PLx Pharma Inc.
    --------------------------------------------------------------------------------
    Item 1(b)	Address of Issuer's Principal Executive Offices:
    9 Fishers Lane, Suite E, Sparta, New Jersey 07871
    --------------------------------------------------------------------------------
    Item 2(a) 	Name of Persons Filing:
    
    This schedule ("Schedule") is being filed by Level One Partners, LLC, a Virginia limited liability company, which directly owns the common shares being reported in this Schedule.  Robert D. Hardie and Molly G. Hardie may be deemed to share voting and dispositive power with respect to such shares.  Robert D. Hardie also individually owns shares reported in this Schedule.  Each filer disclaims beneficial ownership with respect to any shares other than the shares owned directly by such filer.
    
    --------------------------------------------------------------------------------
    Item 2(b)	Address of Principal Business Office or, if None, Residence:
    
    Level One Partners, LLC
    210 Ridge McIntire Road, Suite 350
    Charlottesville, Virginia 22903
    
    Robert D. Hardie
    210 Ridge McIntire Road, Suite 350
    Charlottesville, Virginia 22903
    
    Molly G. Hardie
    210 Ridge McIntire Road, Suite 350
    Charlottesville, Virginia 22903
    
    --------------------------------------------------------------------------------
    Item 2(c)	Citizenship:
    
    Level One Partners, LLC - Commonwealth of Virginia
    Robert D. Hardie - United States of America
    Molly G. Hardie - United States of America
    --------------------------------------------------------------------------------
    Item 2(d)	Title of Class of Securities:
    
    Common Stock, par value $0.001
    --------------------------------------------------------------------------------
    Item 2(e)	CUSIP No.:  72942A107
    --------------------------------------------------------------------------------
    
    Item 3		If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)	[_]	Broker or dealer registered under Section 15 of the Act;
    (b)	[_]	Bank as defined in Section 3(a)(6) of the Act;
    (c)	[_]	Insurance company as defined in Section 3(a)(19) of the Act;
    (d)	[_]	Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)	[_]	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)	[_]	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)	[_]	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)	[_]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)	[_]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)	[_]	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)	[_]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
    
    --------------------------------------------------------------------------------
    Item 4		Ownership
    
    Item 4(a)	Amount Beneficially Owned:
    
    Level One Partners, LLC - 2,772,643
    Robert D. Hardie - 3,647,643
    Molly G. Hardie - 2,772,643
    --------------------------------------------------------------------------------
    Item 4(b)	Percent of Class:
    
    Level One Partners, LLC - 12.7%
    Robert D. Hardie - 16.7%
    Molly G. Hardie - 12.7%
    --------------------------------------------------------------------------------
    
    Item 4(c)	Number of shares as to which such person has:
    
    (i)	Sole power to vote or to direct the vote:
    
    Level One Partners, LLC - 0
    Robert D. Hardie - 875,000
    Molly G. Hardie - 0
    --------------------------------------------------------------------------------
    (ii)	Shared power to vote or to direct the vote:
    
    Level One Partners, LLC - 2,772,643
    Robert D. Hardie - 2,772,643
    Molly G. Hardie - 2,772,643
    
    -------------------------------------------------------------------------------
    (iii)	Sole power to dispose or to direct the disposition of:
    
    Level One Partners, LLC - 0
    Robert D. Hardie - 875,000
    Molly G. Hardie - 0
    
    --------------------------------------------------------------------------------
    (iv)	Shared power to dispose or to direct the disposition of:
    
    Level One Partners, LLC - 2,772,643
    Robert D. Hardie - 2,772,643
    Molly G. Hardie - 2,772,643
    
    --------------------------------------------------------------------------------
    Item 5		Ownership of Five Percent or Less of a Class.
    
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
    --------------------------------------------------------------------------------
    Item 6		Ownership of More than Five Percent on Behalf of Another Person.
    
    Not applicable.
    --------------------------------------------------------------------------------
    Item 7		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
    
    Not applicable.
    --------------------------------------------------------------------------------
    Item 8		Identification and Classification of Members of the Group.
    
    Not applicable.
    --------------------------------------------------------------------------------
    Item 9		Notice of Dissolution of Group.
    
    Not applicable.
    --------------------------------------------------------------------------------
    Item 10	Certifications.
    
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11.
    
    
    SIGNATURES
    
    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
    
    Dated:  March 12, 2021
    
    
    Level One Partners, LLC
    
    By:  /s/ Robert D. Hardie
         Robert D. Hardie, Manager
    
    /s/ Robert D. Hardie
    Robert D. Hardie
    
    /s/ Molly G. Hardie
    Molly G. Hardie
    
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
    
    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    
    
    
    EXHIBIT A
    
    JOINT FILING AGREEMENT
    
    The undersigned hereby agree as follows:
    
    	(i)    Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and
    
    	(ii)   Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.
    
    
    Dated:  March  12, 2021
    
    
    Level One Partners, LLC
    
    By:  /s/ Robert D. Hardie
             Robert D. Hardie, Manager
    
    
    /s/ Robert D. Hardie
    Robert D. Hardie
    
    
    /s/ Molly G. Hardie
    Molly G. Hardie
    
    
    
    
    Get the next $PLXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLXP

    DatePrice TargetRatingAnalyst
    12/7/2021$14.00Market Perform → Outperform
    Raymond James
    9/21/2021$29.00Buy
    BWS Financial
    More analyst ratings

    $PLXP
    SEC Filings

    See more
    • SEC Form 15-12G filed by PLx Pharma Inc.

      15-12G - PLx Pharma Winddown Corp. (0001497504) (Filer)

      10/18/23 4:01:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits

      8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)

      9/20/23 4:39:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)

      8/22/23 5:24:50 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLx Pharma Inc.

      SC 13G - PLx Pharma Inc. (0001497504) (Subject)

      4/6/23 9:15:24 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

      SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)

      2/14/23 1:38:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

      SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)

      2/16/22 6:15:38 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Giordano Natasha bought $14,977 worth of shares (4,100 units at $3.65), increasing direct ownership by 378% to 5,186 units

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      3/16/22 8:35:24 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: O'Connor Rita M bought $50,122 worth of shares (13,700 units at $3.66), increasing direct ownership by 106% to 26,670 units

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      3/16/22 8:33:47 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Valentino Michael J

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      2/24/22 8:18:05 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Financials

    Live finance-specific insights

    See more

    $PLXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

      - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c

      11/10/22 5:00:00 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update

      SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022. Followi

      10/26/22 9:00:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update

      - Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in Second Quarter of 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.52)Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022 SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -

      8/12/22 6:50:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets

      SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the "APA") with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC ("Buyer"), to acquire substantially all of the Company's assets (the "Sale"). The Company intends to file voluntary petitions for relief under Chapter 11 of Title 11 of the

      4/12/23 5:24:09 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Receives Nasdaq Delisting Notice

      SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the "Listing Qualifications Department") of the Nasdaq Stock Market LLC ("Nasdaq") that the Listing Qualifications Department has determined to delist the Company's securities from Na

      4/11/23 4:28:31 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

      - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c

      11/10/22 5:00:00 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Leadership Updates

    Live Leadership Updates

    See more
    • PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

      SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as "VAZALORE"), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately. As a member of the Exec

      1/19/22 6:50:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PLx Pharma upgraded by Raymond James with a new price target

      Raymond James upgraded PLx Pharma from Market Perform to Outperform and set a new price target of $14.00

      12/7/21 5:38:25 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BWS Financial initiated coverage on PLx Pharma with a new price target

      BWS Financial initiated coverage of PLx Pharma with a rating of Buy and set a new price target of $29.00

      9/21/21 8:29:27 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on PLx Pharma with a new price target

      Oppenheimer initiated coverage of PLx Pharma with a rating of Outperform and set a new price target of $20.00

      4/9/21 7:21:28 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care